Phase I & II clinical trial expertise

With our extensive expertise in developing and implementing adaptive protocols for Phase I and II trials, we excel in optimising sponsors' studies, ensuring maximum returns while prioritising the safety of our participants

Benefits of using our Phase I & II clinical trials

At Richmond Pharmacology, we prioritise adding value by gathering extensive and highly relevant data within a limited budget. Our focus is on collecting and analysing essential data that directly aligns with the trial objectives.

To ensure efficiency and participant safety, we carefully limit assessments and exposure to only what is necessary and essential for the study.

By tailoring our adaptive limits and implementing robust control mechanisms for each protocol, we effectively manage potential risks and optimise the overall trial process.

Maximising efficiency is at the core of our approach. We employ umbrella protocols that integrate various elements such as ethnic comparison, intensive cardiac assessments, and other biomarkers into a combined framework. This approach not only streamlines the data collection process but also mitigates potential risks associated with subsequent stages of drug development.

By implementing umbrella protocols, we can leverage the data collected across multiple aspects of the study, eliminating redundancy and reducing overall costs. This integrated approach allows us to efficiently assess different parameters and gather comprehensive data while maintaining participant safety as our top priority.

The inclusion of ethnic comparison elements in our umbrella protocols ensures that the trial results can be generalised across diverse populations, providing valuable insights into the safety of the investigational treatments for different ethnic groups.

Additionally, our focus on intensive cardiac assessments and other relevant biomarkers within the umbrella protocol allows for a thorough evaluation of potential cardiovascular risks associated with the investigational drug. This comprehensive approach not only enhances patient safety but also provides valuable data for informed decision making during subsequent stages of drug development.

We maximise return on our sponsors' trials

Using adaptive design to support rational “no-go” or “where to go next” decisions, an entire early phase programme from First-In-Human to Proof of Concept can be performed in one trial protocol, in one trial centre.

Get in touch today

Why Richmond Pharmacology?


Systematic and logical protocols

We adapt the trial design whilst maintaining the validity of the data and integrity of the trial.

Read more +

Competent and fast decisions

We guarantee rapid progression of your trial.

Read more +

Rapid approval

We have an excellent track record for starting studies on time and effectively managing ethics and regulatory submissions.

Read more +

Time efficient

Fast and efficient adaptive protocol development using a transparent and systematic approach.

Read more +

Our adaptive protocols enable immediate implementation of adaptive changes leading to early decision making and efficient use of essential data outputs.

Latest news

Characterisation of the Cardiovascular Effects of a Meal: QTcF Assessment and Further Insights into the Physiological Effects

December 4, 2023
Groundbreaking research paper authored by Dr. Georg Ferber, Dr. Dilshat Djumanov, Dr. Ulrike Lorch, Dr. Edward Jackson, Dr. Joao Almeida Melo, Mr. James Rickard, and Dr. Jorg Taubel. 
Read more

Richmond Pharmacology becomes Richmond in Brand Refresh

December 1, 2023
Refreshed brand reflects company’s growth over 22 years and renewed commitment to turning hope into reality for patients.
Read more


The 44th Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

14 – 16 December 2023
We are thrilled to share our participation in the 44th Annual Meeting of the Japan Society of Clinical Pharmacology.
View event